REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

PLEASE DO NO	T RÉTURN YOU	R FORM TO TH	IE ABOVE ADDRESS.						
1. REPORT DA	TE (DD-MM-YY	3. DATES COVERED (From - To)							
06/11/2011 Quarterly Technical Report						03/12/2010 - 06/11/2011			
4. TITLE AND	SUBTITLE	•			5a. CON	NTRACT NUMBER			
Human Neura	l Cell-Based B	iosensor		N00014-10-C-0066, Mod. P00001					
Human Neural Cell-Based Biosensor						,			
						5b. GRANT NUMBER			
						5c. PROGRAM ELEMENT NUMBER			
6. AUTHOR(S)						5d. PROJECT NUMBER			
Stice, Steven L.									
Chilton, Jamie	2				5e. TASK NUMBER				
Powe, Allan					Je. TAC	DE. TAOK NOMBEN			
					5f. WOI	RK UNIT NUMBER			
7. PERFORMIN	G ORGANIZATI	ON NAME(S) AN	ID ADDRESS(ES)			8. PERFORMING ORGANIZATION REPORT NUMBER			
ArunA Biome	dical, Inc.								
425 River Roa	nd					TR-03112010.6			
Athens, GA 3	0602								
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)						10. SPONSOR/MONITOR'S ACRONYM(S)			
Director, Nava	al Research La		DoD/ONR						
Attn: Code 55		2 02 / 01 111							
4555 Overloo						11. SPONSOR/MONITOR'S REPORT			
	D.C. 20375-53	NUMBER(S)							
,						ONR 5252.235-9714			
12. DISTRIBUTION/AVAILABILITY STATEMENT									
Approved for public release; distribution is unlimited.									
13. SUPPLEMENTARY NOTES									
10. SUFFELIVILIVIANT NUTES									
44 ADOTDAOT									
14. ABSTRACT									
Human neural progenitor cells have a strong potential for use as cell-based biosensors for environmental toxins. The overall goal of									
this project is to develop a human neural cell based biosensor using ArunA's neural cell lines. In this report, we detail progress in									
development for the following areas: (1) neural progenitor isolation from induced pluripotent stem cells, (2) directed differentiation									
of progenitors into dopaminergic neurons, motoneurons and astrocytes using defined medium conditions, (3) cell-based methods to									
detect botulinum toxin, and (4) HTS amenable assays for proliferation, differentiation, cell migration, mitochondrial function,									
reactive oxygen species generation and apoptosis as sensor elements.									
15. SUBJECT TERMS									
neurotoxicity, biosensor, neural cell									
40.050::=:=:	OL 4 OOLE:		47	IAO NIIIRADED		ALE OF BEODONOUS E DESCRIP			
ADOTDAGE						ME OF RESPONSIBLE PERSON			
a. REPORT	PAGES SECOND C. THIS PAGE								
Unclassified	Unclassified Unclassified Unclassified UU 5					EPHONE NUMBER (Include area code)			
				I ,		706-583-0071			



425 River Road Athens, GA 30605

Quarterly Report Human Neural Cell-Based Biosensor

Date: June 11, 2011

Reporting Period: March 12, 2011 – June 11, 2011

Prepared for:

Office of Naval Research (ONR) Director, Naval Research Lab

Attn: Code 5596

4555 Overlook Avenue, SW Washington, D.C. 20375-5320

Contract Number: N00014-10-C-0066, Amendment/Modification P00001

Submitted by:

Dr. Steven L. Stice, Principle Investigator ArunA Biomedical, Inc. 425 River Road Athens, GA 30602

Phone: 706-583-0071 Fax: 706-262-2821

Email: sstice@arunabiomedical.com

Distribution Statement A:

Approved for public release; distribution is unlimited.

UNCLASSIFIED

Distribution of Quarterly Report

			NUMBER OF COPIES		
ADDRESSEE	DODAAC CODE	REPORT ENCLOSED	UNCLASSIFIED/ UNLIMITED	UNCLASSIFIED/ LIMIT ED AND CLASSIFIED	
Program Officer: Dr. Laura Kienker ONR Code: 342 E-Mail: laura.kienker@navy.mil	N00014	Full technical report	1	1	
Administrative Contracting Officer: Office of Naval Research ONR 0254: Russelle Dunson 875 North Randolph St. Arlington, VA 22203-1995 E-mail: russelle.dunson@navy.mil	\$1103A	SF 298 only	1	1	
Director, Naval Research Lab Attn: Code 5596 4555 Overlook Avenue, SW Washington, D.C. 20375- 5320 E-mail: reports@library.nrl.navy.mil	N00173	Full technical report	1	1	
Defense Technical Information Center 8725 John J. Kingman Road STE 0944 Ft. Belvoir, VA 22060-6218 E-mail: tr@dtic.mil	HJ4701	Full technical report	2	2	

Summary

Human neural progenitor cells have a strong potential for use as cell-based biosensors for environmental toxins. The overall goal of this project is to develop a human neural cell based biosensor using ArunA's neural cell lines. In this report, we detail progress in development for the following areas: (1) neural progenitor isolation from induced pluripotent stem cells, (2) directed differentiation of progenitors into dopaminergic neurons, motoneurons and astrocytes using defined medium conditions, (3) cell-based methods to detect botulinum toxin, and (4) HTS amenable assays for proliferation, differentiation, cell migration, mitochondrial function, reactive oxygen species generation and apoptosis as sensor elements.

(1) Neural progenitor isolation from induced pluripotent stem cells

Our previous studies identified novel markers that could be used to isolate neural progenitors from induced pluripotent stem cells (iPSCs). We also developed methods to generate iPSCs. Using these methods, we have generated a new iPSC-derived neural progenitor line. We are now amplifying this line into working stocks for beta testing and potential commercial distribution.

(2) Directed differentiation using defined media conditions

We are continuing development of methods for directed differentiation of neural progenitors into dopaminergic, motoneurons and astrocytes. Substantial progress has been made with astrocyte differentiation procedure; recent work continues to optimize conditions necessary for establishing a robust, reliable differentiation protocol. Work also continues on optimizing the differentiation protocols for dopaminergic and motor neurons. We have recently set up a new phenotype screening assay for dopaminergic differentiation in addition to the standard markers tested for this cell type. We are also in the midst of beta testing a dopaminergic progenitor cell line developed for potential commercial distribution.

(3) Development of cell based methods to detect botulinum toxin

There has been substantial progress in the development of an hN2[™] cell based sensor for botulinum toxin (BoNT). We established the expression of SNAP-25, the target for BoNT, in hN2[™] cells and demonstrated that treatment of hN2[™] with BoNT-A caused SNAP-25 cleavage of in a dose-dependent fashion. This cleavage was specific to the BoNT treatment since it blocked by co-treatment with inhibitors of BoNT action. The manuscript of these findings has been submitted for publication and is under review.

(4) Development of HTS amenable assays as sensor elements for neurotoxicity

We continue to make rapid, substantial progress in developing fluorescence based assays as sensor elements in cell-based biosensors.

Alamar Blue assay: We have optimized conditions for using both hNP1[™] and hN2[™] cells with the Alamar Blue assay, which measures mitochondrial reductase activity in both cell types. We have also assembled a small set of known neurotoxins to complete proof-of-concept studies for this assay.

Cellular ATP assay: We are in the midst of developing a cellular ATP assay for both hNP1[™] and hN2[™] cells. We are currently exploring the ability of this assay to measure both proliferation potential and cellular metabolism, thus increasing the assay's utility.

ROS assay: The development of a reactive oxygen species (ROS) assay is currently on hold – the novel dyes under development show instability during shipping, making further assay development infeasible. Additional optimization of the dye chemistry is needed to overcome this problem.

Neurite outgrowth assay: We previously established a neurite outgrowth assay for detecting neurotoxicants using the already differentiated, mixed neuronal hN2TM cell line. Now, we are expanding the utility of this assay using the ImageXpress high content imaging platform. We are currently testing the assay's ability to measure not only toxicant effects on neurite outgrowth in the *differentiated* hN2TM neuronal cells and but also growth factor effects on neurite outgrowth on the *differentiating* hNP1TM neural progenitors. The expanded capability would allow detection of both positive and negative modulators of neuronal differentiation.

Stice Q2 2011 DoD Progress Report v2

Cell migration assay: We have developed an HTS-amenable cell migration assay using hNP1™ neural progenitors. Previous studies show that the assay can identify inhibitors and stimulators of migration. We have assembled a small set of known neurotoxins to complete proof-of-concept studies for this assay. We are also exploring the ability of this assay to measure proliferation using high content imaging, thus expanding the assay's utility. Our progress to date will be presented in poster format at International Society for Stem Cell Research 9th Annual Meeting, June 15 - 18, 2011, Toronto, Canada. We are in the process of marketing our neural progenitors with the migration assay as a screening tool for drug discovery as well as toxicology investigators.